|
1
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA
expression profile in human osteosarcoma: Role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang J, Shen L, Yang Q and Zhang C:
Overexpression of metadherin mediates metastasis of osteosarcoma by
regulating epithelial-mesenchymal transition. Cell Prolif.
47:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Díaz-Rodríguez L, García-Martínez O,
Morales MA, Rodríguez-Pérez L, Rubio-Ruiz B and Ruiz C: Effects of
indomethacin, nimesulide, and diclofenac on human MG-63
osteosarcoma cell line. Biol Res Nurs. 14:98–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sard L, Accornero P, Tornielli S, Delia D,
Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti
MA, et al: The tumor-suppressor gene FHIT is involved in the
regulation of apoptosis and in cell cycle control. Proc Natl Acad
Sci USA. 96:8489–8492. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ji L, Fang B, Yen N, Fong K, Minna JD and
Roth JA: Induction of apoptosis and inhibition of tumorigenicity
and tumor growth by adenovirus vector-mediated fragile histidine
triad (FHIT) gene overexpression. Cancer Res. 59:3333–3339.
1999.PubMed/NCBI
|
|
6
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sampo M, Koivikko M, Taskinen M, Kallio P,
Kivioja A, Tarkkanen M and Böhling T: Incidence, epidemiology and
treatment results of osteosarcoma in Finland - a nationwide
population-based study. Acta Oncol. 50:1206–1214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jaffe N: Osteosarcoma: Review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Strauss SJ, Ng T, Mendoza-Naranjo A,
Whelan J and Sorensen PH: Understanding micrometastatic disease and
Anoikis resistance in Ewing family of tumors and osteosarcoma.
Oncologist. 15:627–635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zuo H, Chan GP, Zhu J, Yeung WW, Chan AS,
Ammer H and Wong YH: Activation state-dependent interaction between
Gαq subunits and the Fhit tumor suppressor. Cell Commun Signal.
11:592013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morikawa H, Nakagawa Y, Hashimoto K, Niki
M, Egashira Y, Hirata I, Katsu K and Akao Y: Frequent altered
expression of fragile histidine triad protein in human colorectal
adenomas. Biochem Biophys Res Commun. 278:205–210. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu B, Ying X, Wang J, Piriyapongsa J,
Jordan IK, Sheng J, Yu F, Zhao P, Li Y, Wang H, et al:
Identification of a tumor-suppressive human-specific microRNA
within the FHIT tumor-suppressor gene. Cancer Res. 74:2283–2294.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siprashvili Z, Sozzi G, Barnes LD, McCue
P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L,
et al: Replacement of Fhit in cancer cells suppresses
tumorigenicity. Proc Natl Acad Sci USA. 94:13771–13776. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garinis GA, Gorgoulis VG, Mariatos G,
Zacharatos P, Kotsinas A, Liloglou T, Foukas P, Kanavaros P,
Kastrinakis NG, Vassilakopoulos T, et al: Association of allelic
loss at the FHIT locus and p53 alterations with tumour kinetics and
chromosomal instability in non-small cell lung carcinomas (NSCLCs).
J Pathol. 193:55–65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin HY, Hung SK, Lee MS, Chiou WY, Huang
TT, Tseng CE, Shih LY, Lin RI, Lin JM, Lai YH, et al: DNA methylome
analysis identifies epigenetic silencing of FHIT as a determining
factor for radiosensitivity in oral cancer: An outcome-predicting
and treatment-implicating study. Oncotarget. 6:915–934. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gemma A, Hagiwara K, Ke Y, Burke LM, Khan
MA, Nagashima M, Bennett WP and Harris CC: FHIT mutations in human
primary gastric cancer. Cancer Res. 57:1435–1437. 1997.PubMed/NCBI
|
|
18
|
Sevignani C, Calin GA, Cesari R, Sarti M,
Ishii H, Yendamuri S, Vecchione A, Trapasso F and Croce CM:
Restoration of fragile histidine triad (FHIT) expression induces
apoptosis and suppresses tumorigenicity in breast cancer cell
lines. Cancer Res. 63:1183–1187. 2003.PubMed/NCBI
|
|
19
|
Fang JM, Arlt MF, Burgess AC, Dagenais SL,
Beer DG and Glover TW: Translocation breakpoints in FHIT and FRA3B
in both homologs of chromosome 3 in an esophageal adenocarcinoma.
Genes Chromosomes Cancer. 30:292–298. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huiping C, Jonasson JG, Agnarsson BA,
Sigbjornsdottir BI, Huebner K and Ingvarsson S: Analysis of the
fragile histidine triad (FHIT) gene in lobular breast cancer. Eur J
Cancer. 36:1552–1557. 2000. View Article : Google Scholar : PubMed/NCBI
|
